Page last updated: 2024-11-08

farnesyl pyrophosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

farnesyl pyrophosphate: a sesquiterpene that dimerizes to SQUALENE; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-trans,6-trans-farnesyl diphosphate : The trans,trans-stereoisomer of farnesyl diphosphate. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID445713
CHEMBL ID69330
CHEBI ID17407
MeSH IDM0045986

Synonyms (52)

Synonym
gtpl3050
all-trans-farnesyl pyrophosphate
(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl trihydrogen diphosphate
(2e,6e)-farnesol diphosphate
(2e,6e)-farnesyl pyrophosphate
2-trans,6-trans-farnesyl pyrophosphate
(e,e)-farnesyl pyrophosphate
(all-e)-farnesyl diphosphate
trans-trans-farnesyl diphosphate
CHEBI:17407 ,
diphosphoric acid, mono(3,7,11-trimethyl-2,6,10-dodecatrienyl) ester, (e,e)-
diphosphoric acid, mono[(2e,6e)-3,7,11-trimethyl-2,6,10-dodecatrienyl] ester
2,6,10-dodecatrien-1-ol, 3,7,11-trimethyl-, trihydrogen pyrophosphate, (e,e)-
trans-farnesyl pyrophosphate
trans,trans-farnesyl pyrophosphate
sq 32709
372-97-4
FARNESYL-PP ,
farnesyl diphosphate
2-trans,6-trans-farnesyl diphosphate
(2e,6e)-farnesyl diphosphate
farnesyl pyrophosphate
C00448
(e,e)-farnesyl diphosphate
trans,trans-farnesyl diphosphate
farnesylpyrophosphate
LMPR0103010002
phosphono [(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trienyl] hydrogen phosphate
DB07780
CHEMBL69330 ,
phosphono 3,7,11-trimethyldodeca-2,6,10-trienyl hydrogen phosphate
diphosphoric acid, mono((2e,6e)-3,7,11-trimethyl-2,6,10-dodecatrienyl) ester
diphosphoric acid,p-(3,7,11-trimethyl-2,6,10-dodecatrienyl) ester
bdbm50366477
farnesyl trihydrogen pyrophosphate
farnesol pyrophosphate
unii-79w6b01d07
diphosphoric acid, mono(3,7,11-trimethyl-2,6,10-dodecatrienyl) ester
79w6b01d07 ,
2,6,10-dodecatrien-1-ol, 3,7,11-trimethyl-, trihydrogen pyrophosphate
EPITOPE ID:153909
BRD-A57226833-001-01-1
diphosphoric acid, p-(3,7,11-trimethyl-2,6,10-dodecatrienyl) ester
VWFJDQUYCIWHTN-YFVJMOTDSA-N
farnesyldiphosphat
trans-trans-farnesyl pyrophosphate
Q2699676
trans,trans-farnesyl diphosphate (fpp)
diphosphoric acid, p-(3,7,11-trimethyl-2,6,10-dodecatrien-1-yl) ester
DTXSID701020624
CS-0059409
HY-113037

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" When combined with lovastatin, compound 5 prevented lovastatin-induced FPP depletion and impairment of protein farnesylation."( A novel bisphosphonate inhibitor of squalene synthase combined with a statin or a nitrogenous bisphosphonate in vitro.
Hohl, RJ; Shull, LW; Smits, JP; Wasko, BM; Wiemer, DF, 2011
)
0.37

Bioavailability

ExcerptReferenceRelevance
" Although improvement in NO bioavailability has been attributed to the lowering of serum cholesterol levels, recent studies suggest that HMG-CoA reductase inhibitors, statins, may have direct effects on NO bioavailability by little known mechanisms that are independent of serum cholesterol levels."( Cerivastatin potentiates nitric oxide release and enos expression through inhibition of isoprenoids synthesis.
Dobrucki, IT; Kalinowski, L; Malinski, T, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
farnesyl diphosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (84)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Metabolism of steroids111135
Cholesterol biosynthesis2249
Metabolism of vitamins and cofactors146155
Metabolism of cofactors1947
Ubiquinol biosynthesis824
Porphyrin metabolism2344
Heme biosynthesis1530
Steroid Biosynthesis2142
Porphyrin Metabolism1636
Smith-Lemli-Opitz Syndrome (SLOS)2142
CHILD Syndrome2142
Desmosterolosis2142
Chondrodysplasia Punctata II, X-Linked Dominant (CDPX2)2142
Lysosomal Acid Lipase Deficiency (Wolman Disease)2142
Ibandronate Action Pathway2143
Simvastatin Action Pathway2143
Pravastatin Action Pathway2143
Rosuvastatin Action Pathway2143
Alendronate Action Pathway2143
Acute Intermittent Porphyria1636
Porphyria Variegata (PV)1636
Congenital Erythropoietic Porphyria (CEP) or Gunther Disease1636
Hereditary Coproporphyria (HCP)1636
Hypercholesterolemia2142
Lovastatin Action Pathway2143
Zoledronate Action Pathway2143
Cerivastatin Action Pathway2143
Risedronate Action Pathway2143
Pamidronate Action Pathway2143
Fluvastatin Action Pathway2143
Atorvastatin Action Pathway2143
Cholesteryl Ester Storage Disease2142
Hyper-IgD Syndrome2142
Mevalonic Aciduria2142
Wolman Disease2142
Secondary Metabolites: Methylerythritol Phosphate and Polyisoprenoid Biosynthesis1121
Secondary Metabolites: Ubiquinol Biosynthesis922
Metabolism of proteins1058144
Secondary Metabolites: Ubiquinol Biosynthesis 2923
Terpenoid Backbone Biosynthesis1322
Cholesterol biosynthesis and metabolism CE(14:0)2250
Cholesterol biosynthesis and metabolism CE(10:0)2250
Cholesterol Biosynthesis and Metabolism CE(12:0)2250
Cholesterol Biosynthesis and Metabolism CE(16:0)2250
Cholesterol biosynthesis and metabolism CE(18:0)2250
Post-translational protein modification666112
Asparagine N-linked glycosylation16478
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein5068
Synthesis of substrates in N-glycan biosythesis3756
Synthesis of Dolichyl-phosphate617
Epoxysqualene Biosynthesis612
Farnesene Biosynthesis68
Disease1278231
Diseases of metabolism69121
Diseases of glycosylation2243
Diseases associated with glycosylation precursor biosynthesis621
Defective DHDDS causes RP5922
Steroids metabolism ( Steroids metabolism )1627
2 Farnesyl diphosphate + NADPH => NADP+ + Squalene + 2 Pyrophosphate ( Steroids metabolism )16
Cholesterol metabolism with Bloch and Kandutsch-Russell pathways039
Cholesterol Biosynthesis and Metabolism2248
Mevalonate Pathway1126
Molting Hormone Biosynthesis821
Juvenile Hormone Synthesis522
Sesquiterpenoid Biosynthesis414
Triterpenoid Biosynthesis1322
Cholesterol synthesis disorders015
Ergosterol biosynthesis332
superpathway of sterol biosynthesis050
trans, trans-farnesyl diphosphate biosynthesis I05
farnesol biosynthesis03
ubiquinone (coenzyme Q) biosynthesis026
DON mycotoxin biosynthesis02
Biochemical pathways: part I0466
FPP biosynthesis05
Capsidiol biosynthesis111
GGPP biosynthesis II (plastidic)06
Oleoresin sesquiterpene volatiles biosynthesis07
Polyisoprenoid biosynthesis06
Sterol biosynthesis525
Cholesterol biosynthesis I118
Cholesterol biosynthesis II (via 24,25-dihydrolanosterol)117
Cholesterol biosynthesis III (via desmosterol)118

Protein Targets (8)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Squalene synthaseRattus norvegicus (Norway rat)Ki2.60000.00500.65582.6000AID204983
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)Kd0.00200.00200.00200.0020AID1121278
Protein farnesyltransferase subunit betaHomo sapiens (human)Kd0.00200.00200.00200.0020AID1121278
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Geranylgeranyl pyrophosphate synthaseHomo sapiens (human)Km0.71000.71000.71000.7100AID326144
Squalene synthaseHomo sapiens (human)Km2.30002.30002.30002.3000AID326563
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)Km0.07350.04000.07350.1070AID239737; AID71338
Protein farnesyltransferase subunit betaHomo sapiens (human)Km0.07350.04000.07350.1070AID239737; AID71338
Geranylgeranyl pyrophosphate synthaseSaccharomyces cerevisiae S288CKm3.20003.20003.20003.2000AID326143
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
isoprenoid metabolic processGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
geranyl diphosphate biosynthetic processGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
geranylgeranyl diphosphate biosynthetic processGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
farnesyl diphosphate biosynthetic processGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
isoprenoid biosynthetic processGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
steroid biosynthetic processSqualene synthaseHomo sapiens (human)
farnesyl diphosphate metabolic processSqualene synthaseHomo sapiens (human)
cholesterol biosynthetic processSqualene synthaseHomo sapiens (human)
transforming growth factor beta receptor signaling pathwayProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesylationProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein geranylgeranylationProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of Rac protein signal transductionProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
skeletal muscle acetylcholine-gated channel clusteringProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of tubulin deacetylationProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of deacetylase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of skeletal muscle acetylcholine-gated channel clusteringProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
lipid metabolic processProtein farnesyltransferase subunit betaHomo sapiens (human)
protein farnesylationProtein farnesyltransferase subunit betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
dimethylallyltranstransferase activityGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
farnesyltranstransferase activityGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
geranyltranstransferase activityGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
protein bindingGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
identical protein bindingGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
metal ion bindingGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
prenyltransferase activityGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
farnesyltranstransferase activitySqualene synthaseHomo sapiens (human)
protein bindingSqualene synthaseHomo sapiens (human)
metal ion bindingSqualene synthaseHomo sapiens (human)
farnesyl-diphosphate farnesyltransferase activitySqualene synthaseHomo sapiens (human)
squalene synthase activitySqualene synthaseHomo sapiens (human)
protein farnesyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein geranylgeranyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
Rab geranylgeranyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
microtubule bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
receptor tyrosine kinase bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
alpha-tubulin bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
molecular adaptor activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
CAAX-protein geranylgeranyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesyltransferase activityProtein farnesyltransferase subunit betaHomo sapiens (human)
protein farnesyltransferase activityProtein farnesyltransferase subunit betaHomo sapiens (human)
protein bindingProtein farnesyltransferase subunit betaHomo sapiens (human)
zinc ion bindingProtein farnesyltransferase subunit betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
nucleoplasmGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
cytoplasmGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
cytosolGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
Z discGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
perinuclear region of cytoplasmGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
endoplasmic reticulumSqualene synthaseHomo sapiens (human)
endoplasmic reticulum membraneSqualene synthaseHomo sapiens (human)
membraneSqualene synthaseHomo sapiens (human)
endoplasmic reticulum membraneSqualene synthaseHomo sapiens (human)
cytosolProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
plasma membraneProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
CAAX-protein geranylgeranyltransferase complexProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
microtubule associated complexProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesyltransferase complexProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
cytoplasmProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
cytosolProtein farnesyltransferase subunit betaHomo sapiens (human)
microtubule associated complexProtein farnesyltransferase subunit betaHomo sapiens (human)
protein farnesyltransferase complexProtein farnesyltransferase subunit betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID326560Activity of Trypanosoma cruzi microsomal or mitochondrial squalene synthase2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivatives.
AID326559Activity of Trypanosoma cruzi glycosomal squalene synthase2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivatives.
AID326557Activity of Trypanosoma cruzi truncated squalene synthase 24/362007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivatives.
AID326558Activity of human double-truncated squalene synthase2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivatives.
AID326564Activity of Saccharomyces cerevisiae C-terminal truncated squalene synthase2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivatives.
AID1121278Binding affinity to FTase (unknown origin)2013MedChemComm, Mar, Volume: 4, Issue:3
Prenyltransferase Inhibitors: Treating Human Ailments from Cancer to Parasitic Infections.
AID326561Activity of Leishmania mexicana glycosomal squalene synthase2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivatives.
AID242845Catalytic constant against Farnesyltransferase2004Bioorganic & medicinal chemistry letters, Oct-04, Volume: 14, Issue:19
Synthesis of acyloxymethyl ester prodrugs of the transferable protein farnesyl transferase substrate farnesyl methylenediphosphonate.
AID204988Competitive inhibitory activity against microsomal Squalene synthase1991Journal of medicinal chemistry, Jun, Volume: 34, Issue:6
Isoprenyl phosphinylformates: new inhibitors of squalene synthetase.
AID242941Ratio of Kcat to Km for farnesyltransferase2004Bioorganic & medicinal chemistry letters, Oct-04, Volume: 14, Issue:19
Synthesis of acyloxymethyl ester prodrugs of the transferable protein farnesyl transferase substrate farnesyl methylenediphosphonate.
AID326143Activity at Saccharomyces cerevisiae GGPPS2007Proceedings of the National Academy of Sciences of the United States of America, Jun-12, Volume: 104, Issue:24
Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases.
AID326562Activity of Leishmania mexicana microsomal or mitochondrial squalene synthase2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivatives.
AID326144Activity at human GGPPS2007Proceedings of the National Academy of Sciences of the United States of America, Jun-12, Volume: 104, Issue:24
Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases.
AID326563Activity of human full length squalene synthase expressed in baculovirus2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivatives.
AID204983Inhibitory activity against microsomal Squalene synthase1991Journal of medicinal chemistry, Jun, Volume: 34, Issue:6
Isoprenyl phosphinylformates: new inhibitors of squalene synthetase.
AID239737Michaelis-Menten constant against Farnesyltransferase2004Bioorganic & medicinal chemistry letters, Oct-04, Volume: 14, Issue:19
Synthesis of acyloxymethyl ester prodrugs of the transferable protein farnesyl transferase substrate farnesyl methylenediphosphonate.
AID1309376Ratio of Kcat to Km for recombinant FTase (unknown origin) using dansyl-GCVLS as co-substrate assessed as protein prenylation by spectrofluorometric method2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Exploration of GGTase-I substrate requirements. Part 2: Synthesis and biochemical analysis of novel saturated geranylgeranyl diphosphate analogs.
AID71338Binding affinity constant against mammalian protein Farnesyltransferase2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Grignard-mediated synthesis and preliminary biological evaluation of novel 3-substituted farnesyl diphosphate analogues.
AID1145974Inhibition of Baker's yeast squalene synthetase assessed as incorporation of [1-3H]farnesyl pyrophosphate into squalene at 2 to 6 uM after 2 mins by liquid scintillation spectrometer analysis1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of squalene synthetase by farnesyl pyrophosphate analogues.
AID73582Dissociation constant against yeast farnesyltransferase2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Didehydrofarnesyl diphosphate: an intrinsically fluorescent inhibitor of protein farnesyltransferase.
AID1638642Binding affinity to Staphylococcus aureus HepPPS2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Discovery of Lipophilic Bisphosphonates That Target Bacterial Cell Wall and Quinone Biosynthesis.
AID1346823Human mevalonate kinase (Lanosterol biosynthesis pathway)1997Journal of lipid research, Nov, Volume: 38, Issue:11
Post-translational regulation of mevalonate kinase by intermediates of the cholesterol and nonsterol isoprene biosynthetic pathways.
AID1346896Rat mevalonate kinase (Lanosterol biosynthesis pathway)1990The Journal of biological chemistry, Feb-05, Volume: 265, Issue:4
Purification and regulation of mevalonate kinase from rat liver.
AID1346896Rat mevalonate kinase (Lanosterol biosynthesis pathway)2004Journal of bacteriology, Jan, Volume: 186, Issue:1
Staphylococcus aureus mevalonate kinase: isolation and characterization of an enzyme of the isoprenoid biosynthetic pathway.
AID1346823Human mevalonate kinase (Lanosterol biosynthesis pathway)2008Biochemistry, Mar-25, Volume: 47, Issue:12
Biochemical and structural basis for feedback inhibition of mevalonate kinase and isoprenoid metabolism.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (686)

TimeframeStudies, This Drug (%)All Drugs %
pre-199047 (6.85)18.7374
1990's137 (19.97)18.2507
2000's229 (33.38)29.6817
2010's242 (35.28)24.3611
2020's31 (4.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.14%)5.53%
Reviews37 (5.32%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other658 (94.54%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]